

## THE SUBSCRIPTION PERIOD HAS STARTED IN CESSATECH'S RIGHTS ISSUE

NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, WITHIN OR TO THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND OR IN ANY OTHER JURISDICTION WHERE SUCH RELEASE, DISTRIBUTION OR PUBLICATION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES.

**København, Denmark, October 27, 2022 – Cessatech A/S (“Cessatech” or the “Company”) announces that the subscription period for the Company’s rights issue of shares (the “Rights Issue” or the “Offering”) commenced today. The Rights Issue is also open for subscriptions to the public.**

- One (1) existing share in Cessatech held on the record date of October 25, 2022, entitles to one (1) Unit Right.
- Four (4) Unit Rights entitles to subscription of one (1) Unit. One (1) Unit comprise of six (6) new shares and three (3) warrants of series TO2 free of charge.
- The subscription price is DKK 12 per unit, corresponding to DKK 2 per share.
- The Subscription period of the Rights Issue runs from October 27 up until November 9, 2022, both days included.
- The Offering Memorandum, the application form and other information about the Offering is available on the Company’s website, [www.cessatech.com](http://www.cessatech.com) as well as on [www.nordnet.se](http://www.nordnet.se) and [www.nordnet.dk](http://www.nordnet.dk).

### **Advisors**

Translusion Capital acts as financial advisors to the Company in connection with the Offering. Nordic Issuing is the Company’s issuing agent whereas Elmann Law Firm is the Company’s legal advisor in connection with the Offering.

### **For more information about Cessatech, please contact:**

Jes Trygved, CEO

Phone: +45 9387 2309

E-mail: [jes.trygved@cessatech.com](mailto:jes.trygved@cessatech.com)

[www.cessatech.com](http://www.cessatech.com)

### **About Cessatech A/S**

Cessatech A/S is a Danish pharmaceutical company committed to developing and commercializing evidence-based and innovative medicines for children for the treatment of paediatric acute pain. Its lead asset (CT001) is an analgesic nasal spray for the treatment of acute and planned painful procedures in children. The advantages include needle-free administration, easy administration, a fast-acting therapeutic effect, and being medically approved for children.